(Q42627200)

4 November 2017

title

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment (English)

1 reference

4 November 2017

1 reference

Sujata Vaidyanathan

1

1 reference

4 November 2017

Hilde Bigler

2

1 reference

4 November 2017

ChingMing Yeh

3

1 reference

4 November 2017

Marie-Noelle Bizot

4

1 reference

4 November 2017

Hans Armin Dieterich

5

1 reference

4 November 2017

Dan Howard

6

1 reference

4 November 2017

William P Dole

7

1 reference

4 November 2017

publication date

1 January 2007

1 reference

Clinical Pharmacokinetics

4 November 2017

published in

1 reference

4 November 2017

volume

46

1 reference

4 November 2017

issue

8

1 reference

4 November 2017

page(s)

661-675

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200746080-00003

4 November 2017

exact match

0 references

cites work

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746080-00003

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746080-00003

Renin inhibition: what are the therapeutic opportunities?

21 January 2018

1 reference

12 December 2020

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

1 reference

12 December 2020

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

12 December 2020

Drug dosing in chronic kidney disease

1 reference

12 December 2020

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

12 December 2020

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy

1 reference

12 December 2020

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

12 December 2020

Effects of renal failure on drug transport and metabolism

1 reference

12 December 2020

Protecting renal function in the hypertensive patient: clinical guidelines

1 reference

12 December 2020

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

12 December 2020

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

12 December 2020

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

1 reference

12 December 2020

Drug metabolism in chronic renal failure

1 reference

12 December 2020

Hepatic drug metabolism and transport in patients with kidney disease.

1 reference

12 December 2020

Hypertension, renal disease, and drug considerations

1 reference

12 December 2020

Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor

1 reference

12 December 2020

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

12 December 2020

10.2165/00003088-200746080-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

1038052247

0 references

1 reference